NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
AMEDISYS INC
NASDAQ:AMED (1/31/2025, 8:10:40 PM)
After market: 92.5 0 (0%)92.5
+0.09 (+0.1%)
The current stock price of AMED is 92.5 USD. In the past month the price increased by 1.88%. In the past year, price decreased by -2.29%.
President Trump has spoken about implementing a family caregiver tax credit during his presidential campaign to ease the burden on caregivers, here's who gains.
UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at the estimates and key items to watch.
UnitedHealth Group Inc. and Amedisys Inc. gave themselves more time to complete a $3.3 billion deal for the insurer to purchase the home-health provider that’s been challenged by the government.
The US Justice Department is moving to block UnitedHealth Group Inc.’s $3.3 billion purchase of Amedisys Inc. over concerns the deal would harm competition in the market for home-health services, according to people familiar with the matter.
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 10.76 | 81.83B | ||
CVS | CVS HEALTH CORP | 8.89 | 71.07B | ||
LH | LABCORP HOLDINGS INC | 17.32 | 20.89B | ||
DGX | QUEST DIAGNOSTICS INC | 18.28 | 18.21B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 14.89 | 14.59B | ||
DVA | DAVITA INC | 19.84 | 14.45B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 176.51 | 14.45B | ||
CHE | CHEMED CORP | 24.53 | 8.42B | ||
HIMS | HIMS & HERS HEALTH INC | 84.73 | 8.14B | ||
CRVL | CORVEL CORP | 24.6 | 5.95B | ||
GH | GUARDANT HEALTH INC | N/A | 5.80B | ||
OPCH | OPTION CARE HEALTH INC | 25.98 | 5.26B |
Amedisys, Inc. engages in the provision of healthcare services. The company is headquartered in Baton Rouge, Louisiana and currently employs 19,000 full-time employees. The firm is engaged in providing care and support in the home. The company delivers clinically distinct care that suits its patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury or care. Its operations involve serving patients across the United States through its three operating divisions: home health, hospice, and high acuity care. Its home health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The home health includes 346 care centers located in 34 states within the United States and the District of Columbia. Its hospice care is designed to provide comfort and support for those who are dealing with a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes.
AMEDISYS INC
3854 American Way Ste A, 5959 S Sherwood Forest Blvd
Baton Rouge LOUISIANA 70816 US
CEO: Paul B. Kusserow
Employees: 19000
Company Website: https://www.amedisys.com/
Investor Relations: http://investors.amedisys.com/
Phone: 12252922031
The current stock price of AMED is 92.5 USD.
The exchange symbol of AMEDISYS INC is AMED and it is listed on the Nasdaq exchange.
AMED stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AMED, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AMED.
AMED does not pay a dividend.
AMED will report earnings on 2025-02-19, after the market close.
The PE ratio for AMED is 21.56. This is based on the reported non-GAAP earnings per share of 4.29 and the current share price of 92.5 USD.
The outstanding short interest for AMED is 7.02% of its float.
ChartMill assigns a technical rating of 4 / 10 to AMED. When comparing the yearly performance of all stocks, AMED is a bad performer in the overall market: 70.07% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to AMED. While AMED has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months AMED reported a non-GAAP Earnings per Share(EPS) of 4.29. The EPS increased by -4.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3.57% | ||
ROA | 3.88% | ||
ROE | 7.23% | ||
Debt/Equity | 0.3 |
ChartMill assigns a Buy % Consensus number of 54% to AMED. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 4.38% and a revenue growth 5.09% for AMED